Sibship and risk of asthma in a total population: A disease comparative approach  by Almqvist, Catarina et al.
J ALLERGY CLIN IMMUNOL
VOLUME 138, NUMBER 4
LETTERS TO THE EDITOR 1219Siteman Comprehensive Cancer Center and the National Cancer Institute Cancer
Center (grant no. P30 CA091842), and NIH/NHLBI R01HL130876.
Disclosure of potential conflict of interest: L. B. Bacharier reports grants from the Na-
tional Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI)
AsthmaNet during the conduct of the study and personal fees from Aerocrine,
GlaxoSmithKline, Genentech/Novartis, Merck Schering, Cephalon, DBV Technolo-
gies, Teva, Boehringer-Ingelheim, AstraZeneca, WebMD, and Sanofi outside the sub-
mitted work. M. Castro reports grants from the NIH during the conduct of the study;
personal fees from Asthmatx/Boston Scientific, IPS/Holaria, Genentech, Merck,
GSK, Genentech, Boehringer-Ingelheim, and Elsevier; grants from Boston Scientific,
Amgen, Ception/Cephalon/Teva, Genetech, Medimmune, Merck, Novartis, GSK,
Sanofi-Aventis, Vectura, NextBio, and KalaBios; and stock options from Sparo,
Inc, all outside the submitted work. A. Beigelman reports grants from the NHLBI/Na-
tional Institute of Allergy and Infectious Diseases/NIH AsthmaNet/ICAC. The rest of
the authors declare that they have no relevant conflicts of interest.
REFERENCES
1. Bacharier LB, Cohen R, Schweiger T, Yin-Declue H, Christie C, Zheng J, et al.
Determinants of asthma after severe respiratory syncytial virus bronchiolitis.
J Allergy Clin Immunol 2012;130:91-100.e3.
2. Beigelman A, Bacharier LB. The role of early life viral bronchiolitis in the
inception of asthma. Curr Opin Allergy Clin Immunol 2013;13:211-6.
3. Beigelman A, Isaacson-Schmid M, Sajol G, Baty J, Rodriguez OM, Leege E, et al.
Randomized trial to evaluate azithromycin’s effects on serum and upper airway
IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus
bronchiolitis. J Allergy Clin Immunol 2015;135:1171-8.e1.
4. Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways
diseases. Chest 2010;138:1202-12.
5. Beigelman A, Mikols CL, Gunsten SP, Cannon CL, Brody SL, Walter MJ.
Azithromycin attenuates airway inflammation in a mouse model of viral
bronchiolitis. Respir Res 2010;11:90.
6. Bisgaard H, Hermansen MN, Buchvald F, Loland L, Halkjaer LB, Bonnelykke K,
et al. Childhood asthma after bacterial colonization of the airway in neonates.
N Engl J Med 2007;357:1487-95.
7. Teo SM, Mok D, Pham K, Kusel M, Serralha M, Troy N, et al. The infant
nasopharyngeal microbiome impacts severity of lower respiratory infection and
risk of asthma development. Cell Host Microbe 2015;17:704-15.
8. Beigelman A, Bacharier LB. Infection-induced wheezing in young children.
J Allergy Clin Immunol 2014;133:603-4. e4.
9. Zhou Y, Holland MJ, Makalo P, Joof H, Roberts CH, Mabey DC, et al. The
conjunctival microbiome in health and trachomatous disease: a case control study.
Genome Med 2014;6:99.
Available online May 18, 2016.
http://dx.doi.org/10.1016/j.jaci.2016.03.054Sibship and risk of asthma in a total
population: A disease comparative
approachTo the Editor:
Asthma is one of the most common chronic diseases in
childhood and adolescence. There is a great body of evidence
that younger siblings have a protective effect against asthma or
atopic manifestations, such as hay fever, atopic eczema, and
allergic sensitization.1,2 Different explanatorymechanisms have
been discussed. One hypothesis is that older siblings promote
early infections in childhood and repeated infections protect
against atopic disorders.3 Another hypothesis is related to the in-
trauterine environment or interpregnancy interval because
closely spaced pregnancies allow less time for recovery from
any immunosuppressive effect,4 and yet another is that the
risk is related to report bias, although the difference in health
care–seeking behavior in first-born children as opposed to 2016 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).younger siblings could also be the case. Effects of sibship or in-
terpregnancy intervals have also been seen for other diseases,
such as some neuropsychiatric disorders, including attention
deficit hyperactivity disorder (ADHD)5 and type 1 diabetes,6
and a comparative disease approach has been requested.7
The aim of this study was to estimate the association between
sibship characteristics and the subsequent diagnosis of asthma,
bronchitis and respiratory tract infection, type 1 diabetes mellitus,
gastroenteritis, and ADHD. We also aimed to test the potential
effect of interpregnancy interval to second-born children as a
measure of the intrauterine environment.
Through linkage of the SwedishMedical Birth Registry and the
Multi-Generation Registry, we identified a cohort of first-born and
second-born singleton children in Sweden from January 1, 1996,
to January 1, 2002, in families with only full siblings.
Asthma and other disease outcomes were measured during 1 year
(2008), when the children were 6 to 12 years of age, to capture
prevalence of the chronic diseases (asthma, type 1 diabetes mellitus,
and ADHD) and tendency to catch and search medical care for
infections. In total, 314,477 childrenwere identified after exclusions.
Disease outcomes were extracted from the Swedish National
Patient Register (NPR) and the Swedish Prescribed Drug Register
(SPDR). For asthma, diabetes, and ADHD, we used diagnoses
from the NPR, dispensed medication in the SPDR, or both. For
asthma medication, 2 or more dispensings of any of the drugs
were required. The outcomes of lower respiratory tract infection,
upper respiratory tract infection, bronchitis/bronchiolitis, and
gastroenteritis were based solely on information from the NPR.
The children were classified as being either (1) first-born
children with no siblings, (2) first-born children with at least 1
sibling, or (3) second-born children at the start of 2008. Second-
born children were further categorized by time between their birth
and that of their older sibling (<2, >_2-4, and >_5 years) to capture
the length of the interpregnancy interval and immunosuppressive
effects in the intrauterine environment.
The potential confounders of sex; birth weight; maternal age at
delivery; prepregnancy body mass index (BMI); smoking during
pregnancy; information on maternal and paternal education;
cohabitation of the parents on December 31, 2007; and parental
history of the outcome diseases were obtained from the Medical
Birth Register, the longitudinal integration database for health
insurance and labor market studies (LISA by Swedish acronym),
the NPR, and the SPDR.
We used logistic regression to estimate odds ratios (ORs) of the
association between sibling status and each of the diseases. The
reference group was first-born children with siblings. Robust SEs
were used to account for familial clustering of observations. Both
crude and adjusted estimates are reported together with 95% CIs
for all models. Additional analyses were done with second-born
children further categorized by time between their birth and that
of their older sibling. Details on study design, definition of
exposure and outcome, and statistical analyses are provided in
this article’s Online Repository at www.jacionline.org.
The study was approved by the regional ethical review board in
Stockholm, Sweden.
Table I shows the background characteristics of the study
population. In total, 13.2% were first-born children without
siblings, 42.8% were first-born children with siblings, and
44.0% were second-born children. First-born children were
smaller at birth compared with second-born children, and there
were differences in maternal age, smoking, parental education,
TABLE I. Child/family characteristics and outcome by sibling status in the study population (n 5 314,477)
First-born children
without siblings,* no. (%)
First-born children
with siblings, no. (%)
Second-born
children, no. (%)
All 41,370 (13.2) 134,707 (42.8) 138,400 (44.0)
Sex
Boy 20,969 (50.7) 69,559 (51.6) 71,260 (51.5)
Girl 20,401 (49.3) 65,148 (48.4) 67,140 (48.5)
Birth weight (g)
<_2,999 7,740 (18.7) 19,663 (14.6) 11,896 (8.6)
3,000-3,499 13,864 (33.5) 45,032 (33.4) 37,586 (27.2)
3,500-3,999 13,085 (31.6) 47,294 (35.1) 53,450 (38.6)
4,000-4,499 5,244 (12.7) 18,333 (13.6) 27,677 (20.0)
>_4,500 1,215 (2.9) 3,763 (2.8) 7,328 (5.3)
Missing 222 (0.5) 622 (0.5) 463 (0.3)
Maternal age (y)
<20 1,974 (4.8) 3,502 (2.6) 425 (0.3)
20-29 19,192 (46.4) 91,571 (68.0) 67,364 (48.7)
30-39 18,563 (44.9) 39,335 (29.2) 68,546 (49.5)
>_40 1,641 (4.0) 299 (0.2) 2,065 (1.5)
Maternal BMI (kg/m2)
<18.5 1,051 (2.5) 3,051 (2.3) 2,710 (2.0)
18.5-24.9 21,871 (52.9) 79,974 (59.4) 76,614 (55.4)
25.0-29.9 8,093 (19.6) 24,616 (18.3) 28,858 (20.9)
>_30 3,568 (8.6) 8,273 (6.1) 11,124 (8.0)
Missing 6,787 (16.4) 18,793 (14.0) 19,094 (13.8)
Family situation: parents living together
No 18,146 (43.9) 17,419 (12.9) 26,739 (19.3)
Yes 21,428 (51.8) 115,897 (86.0) 109,540 (79.2)
Missing 1,796 (4.3) 1,391 (1.0) 2,121 (1.5)
Education level of mothers in 2004
Elementary school 4,596 (11.1) 7,518 (5.6) 7,638 (5.5)
High school 22,125 (53.5) 67,302 (50.0) 72,614 (52.5)
College/university 14,034 (33.9) 59,508 (44.2) 57,482 (41.5)
Missing 615 (1.5) 379 (0.3) 666 (0.5)
Education level of fathers in 2004
Elementary school 6,486 (15.7) 12,533 (9.3) 14,423 (10.4)
High school 22,592 (54.6) 72,069 (53.5) 75,289 (54.4)
College/university 11,084 (26.8) 49,222 (36.5) 47,310 (34.2)
Missing 1,208 (2.9) 883 (0.7) 1,378 (1.0)
Smoking during pregnancy
Nonsmoker 30,414 (73.5) 114,859 (85.3) 118,186 (85.4)
1-9 Cigarettes/d 5,647 (13.7) 9,031 (6.7) 8,396 (6.1)
>_10 Cigarettes/d 2,301 (5.6) 2,856 (2.1) 3,537 (2.6)
Missing 3,008 (7.3) 7,961 (5.9) 8,281 (6.0)
Comorbidity 8,388 (20.3) 25,168 (18.7) 23,736 (17.2)
Outcome variables
Asthma 1,909 (4.6) 5,505 (4.1) 5,073 (3.7)
Bronchitis/bronchiolitis 33 (0.1) 104 (0.01) 72 (0.1)
Lower respiratory tract infection 64 (0.2) 216 (0.2) 140 (0.1)
Upper respiratory tract infection 485 (1.2) 1,376 (1.0) 1,086 (0.8)
Type 1 diabetes 208 (0.5) 554 (0.4) 596 (0.4)
Gastroenteritis 110 (0.3) 229 (0.2) 233 (0.2)
ADHD 658 (1.6) 1,308 (1.0) 1,262 (0.9)
*No siblings at start of follow-up year (2008).
Includes congenital malformations, neoplasm, metabolic disease, mental/behavioral disease, and diseases of the nervous, circulatory, digestive, and genitourinary systems.
Numbers shown are comorbidity before asthma.
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Children who had not yet had a sibling had higher odds of
asthma (adjusted OR, 1.15; 95% CI, 1.08-1.22), diabetes
(adjusted OR, 1.30; 95% CI, 1.09-1.56), gastroenteritis
(adjusted OR, 1.55; 95% CI, 1.19-2.01), and ADHD (adjusted
OR, 1.27; 95% CI, 1.14-1.43) compared with first-born children
with siblings but no significant difference in odds of bronchitis/
bronchiolitis and respiratory tract infections (Fig 1 and seeTable E1 in this article’s Online Repository at www.
jacionline.org). Second-born children had lower odds of asthma
and respiratory diseases compared with first-born children with
siblings but with no significant differences in the odds of dia-
betes, ADHD, and gastroenteritis. Among second-born children,
there was no clear difference in relation to the interpregnancy
interval. Further details on Results and Discussion are provided
in this article’s Online Repository at www.jacionline.org.
FIG 1. ORs and 95% CIs for the association between sibling status and disease outcomes in children 6 to
12 years of age. Second-born children were categorized according to interpregnancy interval (ie, years since
birth of first-born sibling).
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prevalence of some common childhood outcomes in first-born
children with or without siblings and second-born children. First-
born children without siblings had higher odds of asthma,
diabetes, gastroenteritis, and ADHD compared with first-born
children with siblings. This might be related to health care–
seeking behavior in families with only 1 child, reduced likeliness
to have another child if the first has severe disease, or residual
confounding caused by less advantaged social background in
those without siblings or other differences in lifestyle. A recent
meta-analysis on the association between sibship and diabetes
reported a lower risk of childhood-onset type 1 diabetes with
increasing birth order, which might reflect increased exposure to
infections in early life in children born later.8We also confirm that
second-born children had lower odds of asthma and respiratory
diseases compared with first-born children with siblings, but there
was no significant difference in the odds of gastroenteritis, dia-
betes, and ADHD. It is likely that this is related to microorganism
exposure3 or reduced health care–seeking behavior in parents used
to viral infections in their second-born children,more comfortable
with the disease, and less likely to seek evaluation or treatment.
Moreover, findings that there was no clear difference for inter-
pregnancy intervals might argue for health care–seeking behavior
rather than infectious burden or the intrauterine environment.3,4,9
In conclusion, we have shown an association between sibship
characteristics and subsequent diagnosis of asthma and other
disease outcomes in a pattern that indicates an underlying
mechanism compatible with different health care–seeking
behavior and microbial exposure.
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sitions of STAT3 cause either loss
or gain of functionY657SE8 HIES 0.999
Y657NE9 HIES 0.999
Y657insE10 gd T lymphoma
Y657dupE11 T-LGL
Y657_M660dupE12 IHCA, CHC1021T
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K658YE12 IHCA; CHC379T 0.956 Possibly damaging
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Signal transducer and activator of transcription 3 (STAT3)
directly or indirectly regulates the pathways of IL-6, IL-10, IL-11,
IL-17, IL-23, G-CSF, M-CSF, and leptin, among others. STAT3
has 24 exons, which are spliced into 3 isoforms, resulting in pro-
teins of 722 or 770 amino acids.1 Dominant-negative (DN) de
novo and inherited germline mutations in STAT3 predominantly
in the DNA-binding domain and Src homology 2 (SH2) domains
of STAT3 cause hyper-IgE syndrome (Job’s or HIES).2,3
Recently, somatic mutations in STAT3 have been found in up to
40% of patients with large granular lymphocytic leukemia,4 so
far all in the SH2 domain. More recently, germline gain-of-
function (GOF) mutations in STAT3 were shown to underlie
multiorgan immune disease with immunodeficiency and lympho-
proliferation.5 STAT3 mutations have also been identified in leu-
kemia,6 lymphoproliferative disorders,7 aplastic anemia, and
autoimmune disorders.8,9 Dominant negative STAT3 mutations
cause defective IL-6 and IL-10 signaling and diminished DNA
binding.2 In contrast, GOF mutations are hypermorphic with
higher DNA binding, leading to aberrant STAT1 and STAT5
signaling and decreased regulatory T-cell numbers.8
Missensemutations and deletions have been reported, affecting
at least 89 different positions in STAT3 (see Fig E1 in this article’s
Online Repository at www.jacionline.org). Most of the reported
mutations have been in the DNA-binding domain and the SH2 do-
mains of STAT3, where both hypomorphic and hypermorphic mu-
tations have been reported, with some positions supporting both
hypomorphic and hypermorhphic functions, depending on the
amino acid.
We identified 6 positions in the SH2 domain at which distinct
point mutations have been reported to cause either HIES or
lymphoproliferation/autoimmunity (Table I). Polyphen-2 (Poly-
morphism Phenotyping v2) predictions showed that all the substi-
tutions were possibly or probably damaging, except the arginine
substitution at position 647, which was predicted to be benign
(Table I). We functionally characterized the HIES mutations
N647D and K658E and their leukemia and autoimmunity coun-
terparts N647I and K658N. We transfected Cos-7 cells with plas-
mids encoding wild-type or mutant alleles and stimulated them
with Oncostatin M. On stimulating them with Oncostatin M,
the levels of phosphorylated STAT3 (Y705; pSTAT3) were higher
for GOF N647I and K658N and lower for DN N647D and K658E
alleles, compared with the wild-type STAT3 transfected cells
(Fig 1, A; for Methods, see this article’s Online Repository at
www.jacionline.org). Stimulation of transfected Cos-7 cellswith various concentrations of IL-6 demonstrated a similarly
clear demarcation between hypomorphic and hypermorphic
STAT3 alleles (Fig 1, B). Furthermore, transfected Cos-7 cells
showed a dose-dependent response in the wild-type and GOFmu-
tants while the response of the DNmutants was profoundly blunt-
ed (Fig 1, B). Transfection of U3A cells was in agreement with
the Cos-7 data of the STAT3 alleles (Fig 1, C).
Three-dimensional protein structural analyses showed that the
mutated amino acid substitutions radically changed the electro-
static potentials in the mutated positions. Despite the benign
prediction by Polyphen-2 analysis, the DN mutation N647D
changes the electrostatic potential to be much more negative,
which might adversely affect DNA-binding affinity (Fig 1, D).
In contrast, the GOF N647I mutation reshapes the binding
pocket and removes the localized positive electrostatic potential.
The DN missense mutation K658E alters both the local molec-
ular surface shape and the local electrostatic potential from
slightly positive to significantly negative, which would probably
disrupt binding of STAT3 to DNA. In contrast, GOF K658N
does not alter the molecular landscape nearly as much and the
electrostatic potential shift is not nearly as strong as the
K658E (Fig 1, D).
These structural and functional analyses provide in vitro func-
tional confirmation and molecular predictions of different nonsy-
nonymous mutations in STAT3 at exactly the same positions that
can be either hypomorphic or hypermorphic. Therefore, GOF and
loss-of-functionmutations in STAT3 are not so much a function of
the region of STAT3 in which they occur as they are a function of
their effect on local charge and DNA-binding affinity. Presum-
ably, similar variations occur in regions of STAT3 involved in
protein-protein interactions, as well. Rational classification of
METHODS
Study population and design
To study the association between sibling status and disease outcomes,
we identified a cohort of 6- to 12-year-old children in families with only
full siblings. We used the Medical Birth Register, which contains data for
99% of all births in Sweden since 1973, to identify children who were
either a woman’s first or second child and born in Sweden from January
1, 1996, to January 1, 2002. The fathers were identified by means of
linkage to the Multi-Generation Register, which contains information on
biological and adoptive parents of Swedish residents born since 1932, to
include only families with full siblings. Because the effect of sibship
might be different in families with multiples, we excluded families with
multiparous births. Families were also excluded if they contained adopted
children or if mothers had immigrated to Sweden after 15 years of age to
ensure that all their children were born in Sweden. Furthermore, we
required all children to be alive and living in Sweden during follow-up in
2008. In total, 379,706 children were identified, and 314,477 remained
after exclusions.
Asthma and other disease outcomes were measured during 1 year (2008),
when the childrenwere 6 to 12 years of age, to capture prevalent disease for the
chronic diseases (asthma, type 1 diabetes mellitus, and ADHD) and tendency
to catch and search medical care for infections.
Outcome definition
Disease outcomes were extracted from the NPR and SPDR. The Patient
Register includes information on primary diagnoses, as well as up to 7
secondary diagnoses, from all inpatient hospital visits in Sweden since 1987,
along with approximately 80% of all outpatient visits in specialist care in
Sweden since 2001. All diagnoses since 1997 are registered according to the
International Classification of Diseases, Tenth Revision (ICD-10). The SPDR
includes all medication dispensed in Swedish pharmacies since July 1, 2005,
as recorded by using the Anatomic Therapeutic Chemical classification
system (ATC). For asthma, diabetes, andADHD,we used both diagnoses from
the NPR (ICD-10: J45-J46 for asthma, E10 for diabetes, and F90 for ADHD),
dispensed medication in the SPDR (ATC: R03AC, R03BA, R03AK, and/or
R03DC for asthma; A10A for diabetes; and N06BA for ADHD), or both. For
asthma medication, 2 or more dispensings of any of the drugs were required.
The SPDR can be used to reliably assess asthmaE1 and type 1 diabetesE2 in this
age group. The outcomes of lower respiratory tract infection (ICD-10: J09-
J18), upper respiratory tract infection (ICD-10: J00-J06), bronchitis/bronchio-
litis (ICD-10: J20-J22), and gastroenteritis (ICD-10: A09) were based solely
on information from the NPR, either as a primary diagnosis or as one of the
2 first secondary diagnoses.
For asthma, diabetes, and ADHD, we used diagnoses from the NPR,
dispensed medication in the SPDR, or both. Thus the use of an appropriate drug
in the SPDR would qualify a child for a disease category, even if they did not
appear in the NPR, and children who only had an appropriate diagnosis in the
NPRwithout medication in the SPDRwere still classified as having a diagnosis.
Numbers on the overlap between asthmadiagnosis in theNPRandmedication in
the SPDR have been thoroughly displayed in a recent validation study.E1 All
prescribed drugs have been registered in the SPDR from 2005 onward, and
our outcomes were all measured in 2008, when the SPDR register had full
coverage.
Exposure classification
The children were classified as being either (1) first-born children with no
siblings, (2) first-born children with at least 1 sibling, and (3) second-born
children at the start of 2008. Second-born children were further categorized
by time between their birth and that of their older sibling (<2 years, >_2-4 years
if >_2 years but <5 years, or >_5 years) to capture the length of the
interpregnancy interval and immunosuppressive effects in the intrauterine
environment.
Covariates
Child characteristics of sex and birth weight and maternal characteristics
of age at delivery, prepregnancy maternal BMI, and smoking during
pregnancy were retrieved from the Medical Birth Register. Information on
maternal and paternal education in 2004 and cohabitation of the parents on
December 31, 2007, was obtained from the longitudinal integration database
for health insurance and labor market studies (LISA by Swedish
acronym) held by Statistics Sweden. Parental history of the outcome
diseases were extracted by using the same registers, diagnostic codes, and
ATC codes as for the corresponding outcomes in the children. Parental history
of the disease was defined as ever having the corresponding diagnosis
registered in the NPR in 2001-2008 or drugs in the SPDR from July 1,
2005, to December 31, 2008, from the start of the registers until the end of
follow-up.
Statistical analysis
We used logistic regression to estimate ORs of the association between
sibling status and each of the diseases. The reference group was first-born
children with siblings. Robust SEs were used to account for familial clustering
of observations.
Both crude estimates and estimates adjusted for maternal age at delivery,
prepregnancy maternal BMI, smoking during pregnancy, maternal and
paternal education as a proxy for socioeconomic status, and familial history
of the corresponding outcome disease, are reported together with 95% CIs for
all models. Additional analyses were done with second-born children further
categorized by time between their birth and that of their older sibling.
The study was approved by the regional ethical review board in Stockholm,
Sweden.
RESULTS
Table I shows the background characteristics of the study
population. In total, 13.2% were first-born children without
siblings, 42.8% were first-born children with siblings, and
44.0% were second-born children. In both cohorts the first-born
children with and without siblings were smaller at birth
compared with the second-born children. Compared with the
children with siblings (both first- and second-born children),
parents of the children without siblings were more often
living apart during pregnancy and had lower education, and
the mothers were younger and more often smoked during
pregnancy.
DISCUSSION
The main finding of this study is that there is a difference in the
risk of some common childhood outcomes in first-born children
with or without siblings and second-born children. We confirm
that second-born children have higher risk of asthma and
respiratory tract infections in early life but lower risk of later
asthma. First-born children without siblings compared with those
with younger siblings have reduced risk ofmilder respiratory tract
infections but not pneumonia in early life and later have an
increased risk of asthma, type 1 diabetes, and ADHD. Some of
these findings might be assigned to increased microbial pressure
in children with siblings or parental health care–seeking behavior
and decisions made by health care providers, which is of public
health significance.
The strengths of this study include (1) a population- and
register-based longitudinal study design in a unified health
care environment with recording in medical registers of a
well-defined cohort in Sweden; (2) prospectively collected
information on full sibship and maternal background factors,
which precludes recall bias; (3) ascertainment of asthma by
applying predetermined asthma criteria to the NPR (covers all
inpatient and approximately 80% of all outpatient visits in
specialist care) and SPDR (full coverage of all dispensed
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asthma medication) and other outcomesE1 along with a
comparative disease approach; and (4) assessment of risks in a
cohort with established family pattern. In addition, we had
reasonable statistical power, and the results are generalizable to
the general population.
The study should also be interpreted within its limitations. We
were not able to assess other exposures, such as day care or
farming households. Previous studies have reported that the
protective effect of sibship appears strongest for children who
entered day care between the ages of 6 and 12monthsE3; however,
in Sweden the majority of children are older than 1 year (median,
18 months) at the start of day care.E4
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TABLE E1. ORs and 95% CIs for the cohort aged 6 to 12 years for the association between disease outcomes in 2008 and sibship status
Crude OR (95% CI) Adjusted OR (95% CI)y
Asthma
First-born children with sibling 1.00 1.00
First-born children without siblings 1.14 (1.08-1.20) 1.15 (1.08-1.22)
Second-born children 0.89 (0.86-0.93) 0.90 (0.86-0.94)
<2 y* 0.81 (0.71-0.92) 0.75 (0.65-0.86)
2-4 y 0.90 (0.86-0.93) 0.90 (0.86-0.95)
>_5 y 0.91 (0.84-0.99) 0.93 (0.85-1.01)
Bronchitis/bronchiolitis
First-born children with sibling 1.00 1.00
First-born children without siblings 1.03 (0.70-1.53) 0.98 (0.62-1.54)
Second-born children 0.67 (0.50-0.91) 0.63 (0.45-0.89)
<2 y* 0.99 (0.44-2.26) 0.99 (0.40-2.44)
2-4 y 0.60 (0.43-0.84) 0.55 (0.38-0.80)
>_5 y 0.94 (0.54-1.65) 0.99 (0.54-1.80)
Lower respiratory tract infection
First-born children with sibling 1.00 1.00
First-born children without siblings 0.96 (0.73-1.28) 0.94 (0.69-1.30)
Second-born children 0.63 (0.51-0.78) 0.58 (0.46-0.73)
<2 y* 0.64 (0.31-1.29) 0.55 (0.24-1.23)
2-4 y 0.62 (0.49-0.78) 0.58 (0.45-0.75)
>_5 y 0.68 (0.44-1.07) 0.58 (0.34-0.97)
Upper respiratory tract infection
First-born children with sibling 1.00 1.00
First-born children without siblings 1.15 (1.04-1.28) 1.12 (0.99-1.26)
Second-born children 0.77 (0.71-0.83) 0.75 (0.69-0.82)
<2 y* 0.77 (0.60-1.00) 0.76 (0.57-1.00)
2-4 y 0.75 (0.69-0.81) 0.72 (0.66-0.79)
>_5 y 0.87 (0.74-1.02) 0.79 (0.66-0.95)
Type 1 diabetes
First-born children with sibling 1.00 1.00
First-born children without siblings 1.22 (1.04-1.44) 1.30 (1.09-1.56)
Second-born children 1.05 (0.93-1.18) 1.07 (0.94-1.21)
<2 y* 0.99 (0.70-1.42) 1.01 (0.68-1.50)
2-4 y 1.05 (0.93-1.18) 1.08 (0.95-1.24)
>_5 y 1.08 (0.86-1.35) 1.02 (0.78-1.33)
Gastroenteritis
First-born children with sibling 1.00 1.00
First-born children without siblings 1.57 (1.25-1.97) 1.55 (1.19-2.01)
Second-born children 0.99 (0.83-1.19) 1.00 (0.81-1.22)
<2 y* 0.53 (0.25-1.11) 0.54 (0.24-1.23)
2-4 y 1.02 (0.85-1.24) 1.02 (0.83-1.26)
>_5 y 0.98 (0.68-1.42) 0.97 (0.64-1.46)
ADHD
First-born children with sibling 1.00 1.00
First-born sibling without siblings 1.65 (1.50-1.81) 1.27 (1.14-1.43)
Second-born children 0.94 (0.87-1.01) 0.94 (0.87-1.03)
<2 y* 1.55 (1.28-1.87) 1.34 (1.09-1.66)
2-4 y 0.90 (0.83-0.98) 0.94 (0.86-1.03)
>_5 y 0.91 (0.77-1.06) 0.83 (0.69-1.00)
*Second-born children were categorized according to interpregnancy interval (ie, years since birth of first-born sibling).
Adjusted for maternal age, maternal BMI, smoking during pregnancy, family history of asthma, and parental education level.
No siblings at start of follow-up year (2008).
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